Lingvay I, et al. EASD-Lancet Symposium: Treatment of obesity: the future of diabetes treatment? Presented at: European Association for the Study of Diabetes Annual Meeting; Sept. 27-Oct. 1, 2021 (virtual meeting).
Lingvay reports serving on advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, DataRevive, Eli Lilly, Intercept, Janssen, Medscape/WebMD, Merck, Novo Nordisk, Sanofi, TARGET RWE, Valeritas and Zealand; and receiving research grants and payments from Merck, Mylan, Novo Nordisk, Pfizer and Sanofi. Sumithran reports serving on advisory boards and receiving speaker fees from Novo Nordisk.
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Losing 15% of body weight should be a primary treatment goal for most people with type 2 diabetes and could help lead to diabetes remission, according to two speakers.
Ildiko Lingvay, MD, MPH, MSCS, a professor of medicine at the University of Texas Southwestern Medical Center in Dallas, and Priya Sumithran, MBBS (Hons), FRACP, PhD, a senior research fellow in the department of medicine at the University of Melbourne in Australia, said health care professionals treating people with diabetes should be trained in obesity management to prepare for a future of diabetes treatment where weight loss is a major focus.
Lingvay is a professor of medicine at the University of Texas Southwestern Medical Center in Dallas.
“The treatment of obesity should be the future of diabetes treatment,” Lingvay said during a press conference at the European Association for the Study of Diabetes virtual meeting. “It is now our responsibility to work at making it the present of diabetes treatment.”
According to estimates included in a review article published in The Lancet, 40% to 70% of people with type 2 diabetes have obesity, and about 20% to 40% have cardiovascular disease. This leads to three subgroups of people with type 2 diabetes: adiposity-related diabetes, diabetes with CVD and isolated hyperglycemia. Lingvay said treatment should be tailored specifically toward those subtypes.
“We propose a gluco-centric approach for those with beta-cell dysfunction and isolated hyperglycemia, a cardio-centric approach in those with CVD, and a weight-centric approach in everybody else,” Lingvay said.
Weight loss of 15% as primary goal
In the review article, researchers detailed …….